Aguree Sixtus, Zolnoori Maryam, Atwood Thea Patricia, Owora Arthur
Department of Applied Health Science, School of Public Health, Indiana University Bloomington, Bloomington, IN, United States.
Columbia University Irving Medical Center, New York, NY, United States.
Front Aging Neurosci. 2023 Aug 28;15:1242853. doi: 10.3389/fnagi.2023.1242853. eCollection 2023.
There is growing evidence suggesting choline intake might have beneficial effects on cognitive function in the elderly. However, some studies report no relationship between choline intake and cognitive function or improvement in Alzheimer's disease patients. This protocol is for a systematic review of choline intake and Alzheimer's disease that aims to assess the comparative clinical effectiveness of choline supplementation on Alzheimer's disease risk.
literature search will be performed in PubMed, MEDLINE, EMBASE, CINAHL, Scopus, Cochrane, and the Web of Science electronic databases from inception until October 2023. We will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies will be included if they compared two different time points of choline biomarkers measures in men or women (65+) with Alzheimer's Disease. The risk of bias in the included studies will be assessed within the Covidence data-management software.
This review will summarize the clinical trial and quasi-experimental evidence of choline intake on Alzheimer's disease risk for adults aged 65+. The results from all eligible studies included in the analysis will be presented in tables, text, and figures. A descriptive synthesis will present the characteristics of included studies (e.g., age, sex of participants, type, length of intervention and comparator, and outcome measures), critical appraisal results, and descriptions of the main findings.
This systematic review will summarize the existing evidence on the association between Choline intake and AD and to make recommendations if appropriate. The results of this review will be considered with respect to whether there is enough evidence of benefit to merit a more definitive randomized controlled trial. The results will be disseminated through peer-reviewed journals population.
This protocol outlines the methodology for a systematic review of choline intake and AD. The resulting systematic review from this protocol will form an evidence-based foundation to advance nutrition care for individuals with AD or poor cognitive function.
http://www.crd.york.ac.uk/PROSPERO, identifier CRD42023395004.
越来越多的证据表明,胆碱摄入可能对老年人的认知功能有有益影响。然而,一些研究报告称胆碱摄入与认知功能之间没有关系,或者对阿尔茨海默病患者没有改善作用。本方案旨在对胆碱摄入与阿尔茨海默病进行系统评价,以评估补充胆碱对阿尔茨海默病风险的相对临床疗效。
将在PubMed、MEDLINE、EMBASE、CINAHL、Scopus、Cochrane和Web of Science电子数据库中进行文献检索,检索时间从建库至2023年10月。我们将遵循系统评价和Meta分析的首选报告项目(PRISMA)指南。如果研究比较了患有阿尔茨海默病的男性或女性(65岁以上)胆碱生物标志物测量的两个不同时间点,则将其纳入。纳入研究的偏倚风险将在Covidence数据管理软件中进行评估。
本综述将总结胆碱摄入对65岁以上成年人阿尔茨海默病风险的临床试验和准实验证据。分析中纳入的所有合格研究的结果将以表格、文本和图表形式呈现。描述性综合将呈现纳入研究的特征(如参与者的年龄、性别、类型、干预长度和对照以及结局指标)、关键评估结果和主要发现的描述。
本系统评价将总结关于胆碱摄入与阿尔茨海默病之间关联的现有证据,并在适当时提出建议。将考虑本综述的结果,以确定是否有足够的益处证据值得进行更明确的随机对照试验。结果将通过同行评审期刊传播。
本方案概述了对胆碱摄入与阿尔茨海默病进行系统评价的方法。本方案产生的系统评价将形成一个基于证据的基础,以推进对患有阿尔茨海默病或认知功能不佳个体的营养护理。